Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962969 · ClinicalTrials.gov registry record
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1
- Enrollment target
NCT06962969 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT06962969 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The purpose of this real-world study is to look at breast cancer patients receiving Palbociclib using a large real-world database collected under real-world practice. This study also looks at the safety of Ibrance, including any side effects. Side effects are undesired effects of a medicine or other type of treatment. This study will include the data of the following participants: * Adult women (more than18 years of age) with at least one visit with a breast cancer * Patients with locally advanced breast cancer or metastatic breast cancer with a staging classification of stage III, stage IV. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the cancer which is spread from the place where it started to other places in the body. * Patients with a laboratory test positive for hormone receptor and negative for HER2 before or up to 60 days after advanced/metastatic breast cancer diagnosis date. * Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer. This study will look at the safety of palbociclib treatment by looking at the number and severity of the side effects.
Interventions
- DRUG Ibrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2025-10-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06962969
The ClinicalTrials.gov registry entry for NCT06962969 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrance is the first listed.
NCT06962969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06962969 about?
NCT06962969 is a clinical study titled "A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database". The purpose of this real-world study is to look at breast cancer patients receiving Palbociclib using a large real-world database collected under real-world practice. This study also looks at the safety of Ibrance, including any side effects. Side effects are undesired effects of a medicine or other...
What is the current status of trial NCT06962969?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2025-06-30. Estimated completion is 2025-10-23.
What interventions are being tested in trial NCT06962969?
The interventions under investigation include: Ibrance (DRUG).
Who is sponsoring clinical trial NCT06962969?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.